Daraxonrasib Improves Survival in Metastatic Pancreatic Cancer

A novel targeted therapy, daraxonrasib, has demonstrated a meaningful improvement in overall survival for patients with metastatic pancreatic cancer, according to results from the phase 3 RASolute 302 trial which were shared in a news release. The findings suggest that this investigational oral treatment may offer a new option for patients whose disease has progressed after prior therapy, the release noted.

In the global phase 3 study, patients treated with daraxonrasib experienced a median overall survival of 13.2 months compared with 6.7 months for those who received standard chemotherapy. This represents a substantial extension in survival for a patient population historically associated with poor outcomes.

In addition to improving overall survival, daraxonrasib also extended progression-free survival, meaning patients lived longer without their disease worsening.

These results highlight the potential of targeting RAS-driven cancers, which are common in pancreatic cancer and have historically been difficult to treat effectively.

Improved outcomes with a targeted oral therapy

Daraxonrasib is a first-in-class RAS(ON) inhibitor designed to block cancer-driving RAS mutations. These mutations are present in the majority of pancreatic tumors and play a key role in tumor growth and survival.

The phase 3 RASolute 302 trial demonstrated that patients receiving daraxonrasib had significantly improved outcomes compared with those treated with investigator’s choice of chemotherapy. The oral therapy was administered once daily, offering a potentially more convenient option than traditional intravenous chemotherapy.

Importantly, these findings mark one of the first times a targeted therapy has shown this level of overall survival benefit in previously treated metastatic pancreatic cancer, a setting in which treatment options remain limited.

Addressing an urgent need in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and difficult-to-treat cancers. Many patients are diagnosed at an advanced stage, and outcomes following progression on first-line therapy are typically poor.

RAS mutations are found in approximately most pancreatic cancer cases, making them a critical target for new therapies. However, these mutations have historically been considered challenging to inhibit with drugs.

Daraxonrasib was developed to directly target these mutations by inhibiting RAS in its active, or “on,” state. Early-phase studies showed promising antitumor activity and provided the rationale for advancing the drug into a phase 3 trial.

How the RASolute 302 trial was designed

RASolute 302 is a global, randomized, open-label phase 3 trial evaluating daraxonrasib in patients with metastatic pancreatic cancer who had previously received treatment.

Participants were randomly assigned to receive either daraxonrasib or investigator’s choice of standard-of-care chemotherapy. The study was designed to assess whether the targeted therapy could improve key outcomes, including overall survival and progression-free survival.

This design allowed researchers to directly compare the new therapy against commonly used treatment options in a real-world clinical setting.

Previously treated metastatic disease

The trial enrolled adult patients with metastatic pancreatic ductal adenocarcinoma whose disease had progressed after at least one prior line of therapy, such as a fluorouracil- or gemcitabine-based regimen.

Eligible patients were required to have adequate functional status and recovery from prior treatment-related side effects.

This population reflects a group with significant unmet need, as treatment options are limited after initial therapies stop working.

Additional findings

Beyond overall survival, daraxonrasib demonstrated improvements in disease control, including delaying tumor progression.

The therapy’s oral administration may also provide added convenience for patients, reducing the need for frequent clinic visits associated with intravenous chemotherapy.

Based on these findings, the drug’s developer has indicated plans to pursue regulatory submission, which could potentially accelerate access to this therapy for patients with metastatic pancreatic cancer.